British alliance on ninja antibodies
Enlarge image

BusinessUK

British alliance on ninja antibodies

03.04.2012 - London companies PolyTherics and Spirogen collaborate for better antibody-drug-conjugates (ADCs) in the fight against cancer.

London – The buzz around antibody-drug-conjugates (ADCs), the weapons of choice in the fight against cancer, just became more blatant. After last week’s news that a novel ADC company had been founded in Switzerland PolyTherics Limited from London (UK) announced on 2 April that it would join in the treasure hunt for promising ADC candidates. Just like the Swiss ADC Therapeutics Sarl, London-seated PolyTherics relies on the cytotoxic agents provided by Spirogen Limited. The two companies want to combine PolyTherics’ linker technology TheraPEG™ with Spirogen’s potent cytotoxic pyrrolobenzodiazepines („PBDs“). The aim is to connect PBDs via the new linker to antibodys or antibody fragments in a site-specific manner. PolyTherics CEO John Burt is enthusiastic: „This is an exciting opportunity to combine our validated conjugation technology with Spirogen’s potentially best-in-class PBD warheads.“ Also Spirogen CEO Chris Martin is convinced the collaboration will bear fruit: „ADCs will represent a significant medical breakthrough in cancer therapy. PolyTherics’ TheraPEG™ conjugation technology will broaden the applications where our PBD warheads and linkers can create highly potent potentially market-leading ADC candidates.“ Spirogen’s PBDs are DNA minor groove binding agents, which bind and cross-link specific DNA-sites. They block cell division in the targeted (cancer) cells without distorting their DNA helix, thus avoiding the common phenomenon of emergent drug resistance.

http://www.european-biotechnology-news.com/news/news/2012-02/uk-alliance-on-ninja-antibodies.html

Stock MarketsFranceEU

27.03.2015 Europe is once more proving that it can be a good bet for biotech companies going public. A newly established EU-wide lobbying initiative could help the IPO boom on its way.

FinancingPoland

24.03.2015 Poland has announced the closing of a new venture capital fund at US$42m (€32m). The fund, which is the first of its kind in Poland, is dedicated to the Life Sciences with a strong connection to Central and Eastern Europe.

BioeconomyFranceSwedenGermanyNetherlandsFinland

23.03.2015 A BASF-led consortium aims to decrease bio-based production costs using industrial biotechnology. The Horizon2020 funded consortium is the sixth project of the SPIRE Public Private Partnership and has a budget of €14m.

Stock MarketsFranceSwedenUKNorwayIreland

20.03.2015 There are no signs of inertia creeping into the European biotech industry this spring. A total of eight IPOs are set to go public by the end of the year’s first quarter.

FinancingUKEU

17.03.2015 Pharma giants GlaxoSmithKline (GSK) and Johnson & Johnson (J&J) will be key collaborators in a new global fund for dementia research to address the rising threat posed by dementia and Alzheimer’s disease.

FinancingFranceDenmarkSwedenGermany

19.03.2015 French venture capital firm Seventure Partners has raised a further €25m for its microbiome-focused Health for Life Capital Fund. It now stands at €100m.

EventsFranceEUSwitzerlandUKGermany

12.03.2015 With around 1,400 companies and 2,400 participants, the springtime counterpart of BIO-Europe enjoyed a successful premiere in France this year. The overall mood of the European biotech industry was positive, and the French hosts in particular reported new initiatives.

M&ABelgium

11.03.2015 Belgian cell-based therapeutics developer and CMO MaSTherCell SA has been acquired by US biotech Orgenesis Inc. for €23m.

FinancingGermany

10.03.2015 The Gates Foundation has dipped into its purse to bring infectious diseases vaccines to the poorest countries. German vaccine specialist CureVac is set to receive US$52m for their mRNA platform technology.

Stock MarketsIrelandUK

05.03.2015 The IPO wave in the biotech sector shows no signs of slowing down. An Irish life sciences fund set up by former Elan executives plans to raise €325m with its IPO, whilst Summit Therapeutics has announced its IPO pricing of US$34m on Nasdaq.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • ANALYTIK JENA14.00 EUR0.07%
  • 4SC1.28 EUR0.00%
  • ACTELION112.60 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • MEDIGENE11.64 EUR-0.09%
  • 4SC1.28 EUR0.00%

TOP

  • CYTOS1.40 CHF311.8%
  • MEDIGENE11.64 EUR173.9%
  • 4SC1.28 EUR64.1%

FLOP

  • MORPHOSYS54.71 EUR-26.8%
  • WILEX2.96 EUR-13.7%
  • BASILEA106.70 CHF-12.7%

TOP

  • SANTHERA92.00 CHF2259.0%
  • WILEX2.96 EUR393.3%
  • FORMYCON23.15 EUR230.7%

FLOP

  • CYTOS1.40 CHF-53.0%
  • MOLOGEN5.68 EUR-49.9%
  • PAION2.35 EUR-29.6%

No liability assumed, Date: 27.03.2015